Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
about
Emerging drugs for chronic lymphocytic leukaemia.PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.Dual-targeting siRNAsBCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma modelTreatment of follicular non-Hodgkin's lymphoma: the old and the new.Bortezomib in mantle cell lymphoma.Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Novel disease targets and management approaches for diffuse large B-cell lymphoma.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
P2860
Q30353154-73C82430-44E8-4E82-980C-49BF1AC24606Q33767159-D74644A1-04BE-4E79-ACBB-538BF79F37FCQ33867488-160E581E-A4D6-4D26-9EE0-56783AA77C64Q36284637-8325CA23-4E59-4C9E-B935-63273359B159Q36491547-44356705-2E9B-4939-9A9F-184F4F929412Q37003459-C9C0AB27-BB7A-4A44-9058-3A49258644DAQ37136989-5DA9CFD9-0BDF-40D3-8E84-EFFC2F78C363Q37448352-F979D319-ABCA-410B-8780-AD5AB4087664Q37775632-02B3875D-8DAF-4D61-A1B0-FAB114BA449FQ38766548-2C438FE5-4FDD-4F2C-8781-517C61EA35E2Q41070355-DB3A9972-2DD2-49F1-B5D7-B98FB1F43B1AQ41762088-76FE13FB-B658-491D-BDCD-6A83F4A5B369Q46702842-03438DA3-5D31-4425-B444-FEB143EC38CF
P2860
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Pro-apoptotic therapy with the ...... -tumour activity of rituximab.
@en
type
label
Pro-apoptotic therapy with the ...... -tumour activity of rituximab.
@en
prefLabel
Pro-apoptotic therapy with the ...... -tumour activity of rituximab.
@en
P2093
P2860
P1476
Pro-apoptotic therapy with the ...... -tumour activity of rituximab.
@en
P2093
Asher Chanan-Khan
Francisco J Hernandez-Ilizaliturri
Jeyanthi Ramanarayanan
Myron S Czuczman
P2860
P304
P356
10.1111/J.1365-2141.2004.05239.X
P407
P577
2004-12-01T00:00:00Z